Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated
